PlatformPlatform overviewCOA reviewSupplier document collectionSupplier follow-up (Vera)Supplier qualificationRelease workflowsMock inspections (Cato)Chain of custodyPatient traceabilityUnit-level traceabilityPartner RecordAPIPricing
SolutionsCompounding pharmacies503B outsourcing facilitiesClinicsMed spasTelehealth platformsConsultantsSolutions overview
ResourcesMethodologyOrder-level COA traceabilitySupplier packet diligenceResource libraryPublic toolsIntelligenceTrust Center
CompanyAbout VerituraWhy independentPartnersFor counselContact
Sign inGet a demo

Guide: A valid COA under section 503A. What the peptide policy adds.

Section 503A asks for a valid certificate of analysis and does not say what one contains. The draft peptide policy does, for six substances. Last reviewed November 18, 2026.

Appendix B, in numbersHHS draft policy, October 30, 2026

The certificate

  • Stated items14, in note 1
  • Tests in the table20
  • With no qualifier13
  • Tied to injectable forms2, by note 4
  • On a stated condition5

Each result

  • Method name and numberNote 2
  • Validation report numberNote 2

The policy is a draft and is not binding on HHS or the public.

Valid Certificates of Analysis Under Section 503A: What the Peptide Enforcement Discretion Policy Adds

Abstract. Section 503A permits compounding from a bulk drug substance only where the substance is "accompanied by valid certificates of analysis for each bulk drug substance" (21 U.S.C. 353a(b)(1)(A)(iii)). The statute does not say how validity is established. On October 30, 2026, HHS announced a draft policy of enforcement discretion for six peptides whose third and fourth conditions describe the certificate in detail: fourteen stated items, a table of twenty tests, and a method number and validation report number for each result. This paper reads those two conditions against the statutory clause and sets out the record a pharmacy would keep to show each one. It also marks where the policy stops. The policy is a draft that is "not binding on HHS or the public", and it does not place the six peptides on the 503A bulks list.

Veritura. Reviewed November 18, 2026. Written for the pharmacist-in-charge or quality lead at a 503A pharmacy.

1. A requirement without a method

The statutory clause asks two things of a bulk drug substance. Under clause (ii) it must be "manufactured by an establishment that is registered under section 360 of this title (including a foreign establishment that is registered under section 360(i) of this title)". Under clause (iii) it must be "accompanied by valid certificates of analysis for each bulk drug substance".

The first can be looked up. The second cannot, because nothing in section 503A states what a valid certificate contains or who decides. The question has been left to each pharmacy's supplier qualification procedure and to the state board that inspects it.

Two comparisons show how unusual that silence is. An outsourcing facility under section 503B is subject to current good manufacturing practice, and the CGMP regulation says when a supplier's report may be relied on: "provided that at least one specific identity test is conducted on such component by the manufacturer, and provided that the manufacturer establishes the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals" (21 CFR 211.84(d)(2)). A 503A pharmacy is not subject to that regulation. And one state has written the contents down. California's sterile compounding rule requires that a certificate of analysis "includes the compendial name, the grade of the material, and the applicable compendial designations", and that a certificate received from a supplier "must provide the name and address of the manufacturer" (16 CCR 1736.9(d)).

Appendix B of the October policy describes a certificate's contents in more detail than section 503A or the FDA's interim guidance on bulk drug substances does. It applies to six substances.

2. The policy in outline

HHS announced the policy in the Federal Register on October 30, 2026 (FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496). The notice says that "HHS is announcing the availability of a draft" policy, and that the policy "does not establish any rights for any person and is not binding on HHS or the public."

It is a policy of enforcement discretion. HHS says it "does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance" outside section 503A's usual routes for bulk substances "when all of the following circumstances are present". Ten circumstances follow. The first is that the peptide appears in Appendix A, which names the six substances. Our peptide policy pages take each one in turn. The second ties each one to the identity and the routes of administration in Appendix B.

The third and fourth conditions concern the certificate and the firm behind it, and they are the subject of this paper.

3. Condition 3: what the certificate contains

The third condition requires that the bulk drug substance "is from a facility registered under section 510 (21 U.S.C. § 360) and characterized and identified in a valid certificate of analysis (COA) that includes test results consistent with existing guidance-based criteria described by FDA (see Appendix B)."

The policy states its purpose in plain terms. "This helps provide assurance that what a compounder receives from a supplier is what it claims to be and has been tested for identity, purity, potency, and the absence of harmful contaminants such as endotoxins, heavy metals, microbial contamination, and impurities."

Appendix B then does what the statute does not. Its first note lists what the certificate itself states. There are fourteen items, and they fall into five groups.

GroupWhat note 1 asks the certificate to state
The firmThe manufacturer's corporate name, FEI number and address; any firm involved in processing; any repacker or reprocessor, and the laboratory that performed the analysis
The lotThe batch number, the date of synthesis, the date of release, and an expiration or retest date
The substanceThe name, chemical structure, amino acid sequence, molecular formula and molecular weight
The purposeThe grade "Intended for human drug compounding", the intended dosage form, and the storage conditions
The attestationA statement of CGMP compliance, and a date and signature from the quality unit that identify the original manufacturer

The appendix's testing standard is a table of twenty tests. Thirteen carry no qualifier. Two, bioburden and bacterial endotoxins, are tied to injectable forms by note 4, which calls them "Critical Quality Attributes (CQAs) specific to injectable dosage forms". Five apply on a stated condition, such as a peptide of eight or more amino acids, or the presence of cysteine.

Notes 2 and 3 govern how a result is reported. Each certificate "should identify the analytical method used, including the test method name, test method number", together with the document number of the method's validation or verification report. Identification rests on orthogonal methods, defined as "at least two independent analytical procedures relying on distinct physicochemical principles".

A result with no method number beside it therefore does not answer Appendix B, even where the value itself is within its limit.

4. Condition 4: the original manufacturer

The fourth condition turns from the document to the firm. "The original manufacturer of the bulk drug substance (not a subsequent packer, repacker, labeler, or distributor) is registered with FDA under section 510, is in compliance with CGMP and other FD&C requirements and the physical location of the facility is listed on the COA provided to the 503A compounder."

Two features deserve attention. The parenthesis fixes whose registration counts. A distributor's own registration does not satisfy the condition, and a certificate that names only the distributor leaves it unanswered. The same definition appears in the FDA's interim guidance on bulk drug substances, which says that the original manufacturer is "the entity that originally produced the bulk drug substance and not a subsequent packer, repacker, labeler, or distributor."

The second feature is new. Where the substance "is obtained through an FDA-registered repacker, relabeler, or reseller, that entity has itself performed and documented appropriate vendor validation of the bulk drug substance manufacturer and validation of the manufacturer's COA." The intermediary's diligence becomes a document the pharmacy can ask for, and its absence becomes a gap in the pharmacy's own file.

5. The record behind each clause

The policy says what must be true. It does not say what a pharmacy should keep to show it. The table below is our practice and is not a rule of HHS, the FDA or a state board.

ClauseThe record we would keep
"from a facility registered under section 510"The manufacturer's registration, looked up on the FDA's registration site, with the date of the lookup
"a valid certificate of analysis ... consistent with ... Appendix B"The lot's certificate, read item by item against note 1 and test by test against the table
"the physical location of the facility is listed on the COA"The certificate itself, with the plant address beside the address on the registration record
"is in compliance with CGMP"The certificate's CGMP statement, and a dated check of the manufacturer against the FDA's import alerts
"has itself performed and documented appropriate vendor validation"The intermediary's written validation of the manufacturer and of the manufacturer's certificate

The fourth row needs a caution. A pharmacy cannot establish a foreign manufacturer's CGMP status from documents. It can record what the manufacturer attests and what the FDA's public records show on a given day, and it can show that it looked.

6. Where the policy stops

The policy is a draft. As of November 18, 2026 the Federal Register lists one document under its docket, the notice of October 30.

It is revocable. "HHS may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises with a compounded drug product within the scope of this policy."

It does not change the list. The notice says that the FDA's future rulemakings "may propose adding some or all of these peptides to the 503A bulks list based on the available evidence."

It covers six substances, each in one form and for stated routes. A certificate for any other bulk drug substance remains subject to the statutory clause alone, with no federal description of its contents.

It leaves the rest of the Act in place. The tenth condition requires that the product be compounded "in compliance with all other applicable requirements of the FD&C Act", including the prohibition on insanitary conditions and "section 503A's (21 U.S.C. 353a) patient specific prescription requirement."

7. Conclusion

Section 503A has required a valid certificate of analysis since it was enacted in 1997, and we have found no federal text that says what one contains for a 503A pharmacy. The October policy supplies a detailed description for six peptides and makes it a condition of enforcement discretion. Whatever becomes of the draft, Appendix B is now the most specific public statement of what HHS expects a peptide certificate to carry, and a pharmacy can read its suppliers' certificates against it today.

8. Limits of this paper

Quotations from the policy and its notice were checked word for word against the source text on November 11, 2026. The statute, the CGMP regulation and the FDA's interim guidance were read on November 18, 2026. The California rule was read on November 11, 2026. Section 5 is our practice. Nothing here says that a preparation may be compounded.

Sources

A pharmacy that wants a peptide supplier's certificate read against Appendix B before the first order can start with a free supplier check.

We review documents. We do not test material.

One supplier, qualified for you. Free.

Send us your supplier’s name. We check its registration and FEI against the FDA’s records, gather its licenses and accreditations, and read the COA you send against the standard that applies.